User:Penny
From WikiPathways
(Difference between revisions)
(→About Me) |
Current revision (12:28, 29 January 2021) (view source) |
||
| (2 intermediate revisions not shown.) | |||
| Line 12: | Line 12: | ||
* Lung fibrosis (Homo Sapiens) WP3632 [https://www.wikipathways.org/index.php/Pathway:WP3632] | * Lung fibrosis (Homo Sapiens) WP3632 [https://www.wikipathways.org/index.php/Pathway:WP3632] | ||
* COVID-19 AOP WP4891 [https://www.wikipathways.org/index.php/Pathway:WP4891] | * COVID-19 AOP WP4891 [https://www.wikipathways.org/index.php/Pathway:WP4891] | ||
| + | * RAS and Bradykinin pathways in COVID-19 (Homo sapiens) [https://www.wikipathways.org/index.php/Pathway:WP4969] | ||
| + | * Angiotensin II Receptor Type 1 pathway (Homo sapiens) [https://www.wikipathways.org/index.php/Pathway:WP5036] | ||
== Portals == | == Portals == | ||
* AOP Portal [https://www.wikipathways.org/index.php/Portal:AOP] | * AOP Portal [https://www.wikipathways.org/index.php/Portal:AOP] | ||
* COVID Pathways Portal [https://www.wikipathways.org/index.php/Portal:Disease/COVIDPathways] | * COVID Pathways Portal [https://www.wikipathways.org/index.php/Portal:Disease/COVIDPathways] | ||
| + | * Nanomaterials Portal [https://www.wikipathways.org/index.php/Portal:Nanomaterials] | ||
== Links == | == Links == | ||
| - | * ... | + | * Twitter account [https://twitter.com/pennynymark] |
| + | * ResearchGate profile [https://www.researchgate.net/profile/Penny_Nymark] | ||
| + | * Publons profile [https://publons.com/researcher/3184728/penny-nymark/] | ||
== About Me == | == About Me == | ||
Current revision
|
Contents |
My WikiPathways
Pathways of Interest
- Lung fibrosis (Homo Sapiens) WP3624 [1]
- Lung fibrosis (Homo Sapiens) WP3632 [2]
- COVID-19 AOP WP4891 [3]
- RAS and Bradykinin pathways in COVID-19 (Homo sapiens) [4]
- Angiotensin II Receptor Type 1 pathway (Homo sapiens) [5]
Portals
Links
About Me
- Real name: Penny Nymark
- Work: Assistant Professor at Karolinska Institutet
- Location: Sweden
- Professional Interests: AOPs, Toxicogenomics, New Approach Methodologies, Nanomaterials, Risk assessment
- Contact: [email protected]
